Low densities of immune cells indicate unfavourable overall survival in patients suffering from squamous cell carcinoma of the lung.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 06 2024
20 06 2024
Historique:
received:
09
11
2023
accepted:
14
06
2024
medline:
21
6
2024
pubmed:
21
6
2024
entrez:
20
6
2024
Statut:
epublish
Résumé
Carcinogenesis and tumor proliferation are characterized by a complex interaction of cancer cells with the tumor microenvironment. In particular, a tumor-promoting effect can be assumed for the stroma and its fibroblasts. An influence of the immune system on non small cell lung cancer (NSCLC) is now also suspected. In our study, we examined 309 sections of squamous cell carcinoma (SCC), a subtype of NSCLC. We determined the cell densities and areas of the different tissues in SCC using the software QuPath. Spearman rank correlation showed a significant positive correlation between the different tumor cell densities and stromal cell densities, and between tumor cell densities and immune cell densities. Overall survival curves by the Kaplan-Meier method revealed a prominent negative curve in cases of low immune cell density. Based on our results, we can assume a positive influence of the tumor microenvironment, especially the stromal cells, on tumor proliferation in SCC. We have also revealed that low density of immune cells is prognostically unfavorable.
Identifiants
pubmed: 38902361
doi: 10.1038/s41598-024-64956-y
pii: 10.1038/s41598-024-64956-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14250Informations de copyright
© 2024. The Author(s).
Références
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 68, 394–424 (2018).
doi: 10.3322/caac.21492
pubmed: 30207593
Travis, W. D., Brambilla, E., Müller-Hermelink, H. K. & Harris, C. C. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart (IARC Press, 2004).
Travis, W. D. et al. The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 10, 1243–1260 (2015).
Onion, D. et al. Multicomponent analysis of the tumour microenvironment reveals low CD8 T cell number, low stromal caveolin-1 and high tenascin-C and their combination as significant prognostic markers in non-small cell lung cancer. Oncotarget 9, 1760–1771 (2018).
doi: 10.18632/oncotarget.18880
pubmed: 29416729
Valkenburg, K. C., de Groot, A. E. & Pienta, K. J. Targeting the tumour stroma to improve cancer therapy. Nat. Rev. Clin. Oncol. 15, 366–381 (2018).
doi: 10.1038/s41571-018-0007-1
pubmed: 29651130
pmcid: 5960434
Remark, R. et al. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am. J. Respir. Crit. Care Med. 191, 377–390 (2015).
doi: 10.1164/rccm.201409-1671PP
pubmed: 25369536
pmcid: 5447326
Dieu-Nosjean, M.-C. et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 26, 4410–4417 (2008).
doi: 10.1200/JCO.2007.15.0284
Bremnes, R. M. et al. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 6, 824–833 (2011).
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 3, 991–998 (2002).
doi: 10.1038/ni1102-991
pubmed: 12407406
Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).
doi: 10.1038/s41598-017-17204-5
pubmed: 29203879
pmcid: 5715110
Hamilton, P. W. et al. Automated tumor analysis for molecular profiling in lung cancer. Oncotarget 6, 27938–27952 (2015).
doi: 10.18632/oncotarget.4391
pubmed: 26317646
pmcid: 4695036
Smits, A. J. J. et al. The estimation of tumor cell percentage for molecular testing by pathologists is not accurate. Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc 27, 168–174 (2014).
Bhowmick, N. A., Neilson, E. G. & Moses, H. L. Stromal fibroblasts in cancer initiation and progression. Nature 432, 332–337 (2004).
doi: 10.1038/nature03096
pubmed: 15549095
pmcid: 3050735
Mueller, M. M. & Fusenig, N. E. Friends or foes—bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 4, 839–849 (2004).
doi: 10.1038/nrc1477
pubmed: 15516957
Bhowmick, N. A. et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848–851 (2004).
doi: 10.1126/science.1090922
pubmed: 14764882
Chen, Y., McAndrews, K. M. & Kalluri, R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat. Rev. Clin. Oncol. 18, 792–804 (2021).
doi: 10.1038/s41571-021-00546-5
pubmed: 34489603
pmcid: 8791784
Bremnes, R. M. et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 6, 209–217 (2011).
Dunn, G. P., Old, L. J. & Schreiber, R. D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329–360 (2004).
doi: 10.1146/annurev.immunol.22.012703.104803
pubmed: 15032581
Velcheti, V. et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab. Investig. J. Tech. Methods Pathol. 94, 107–116 (2014).
doi: 10.1038/labinvest.2013.130
Lecciso, M. et al. ATP release from chemotherapy-treated dying leukemia cells elicits an immune suppressive effect by increasing regulatory T cells and tolerogenic dendritic cells. Front. Immunol. 8, 1918 (2017).
doi: 10.3389/fimmu.2017.01918
pubmed: 29312358
pmcid: 5744438
Mondanelli, G. et al. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells. Immunity 46, 233–244 (2017).
doi: 10.1016/j.immuni.2017.01.005
pubmed: 28214225
pmcid: 5337620
Kilic, A., Landreneau, R. J., Luketich, J. D., Pennathur, A. & Schuchert, M. J. Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J. Surg. Res. 167, 207–210 (2011).
doi: 10.1016/j.jss.2009.08.029
pubmed: 19896677
Goc, J. et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 74, 705–715 (2014).
doi: 10.1158/0008-5472.CAN-13-1342
pubmed: 24366885
Al-Shibli, K. et al. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology 55, 301–312 (2009).
doi: 10.1111/j.1365-2559.2009.03379.x
pubmed: 19723145
Broussard, E. K. & Disis, M. L. TNM staging in colorectal cancer: T is for T cell and M is for memory. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29, 601–603 (2011).
doi: 10.1200/JCO.2010.32.9078